These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8949584)

  • 1. The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy.
    Weiss JM; Morgan PH; Lutz MW; Kenakin TP
    J Theor Biol; 1996 Aug; 181(4):381-97. PubMed ID: 8949584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulus amplification, efficacy, and the operational model. Part II--ternary complex occupancy mechanisms.
    Trzeciakowski JP
    J Theor Biol; 1999 Jun; 198(3):347-74. PubMed ID: 10366491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling activation and desensitization of G-protein coupled receptors provides insight into ligand efficacy.
    Riccobene TA; Omann GM; Linderman JJ
    J Theor Biol; 1999 Sep; 200(2):207-22. PubMed ID: 10504286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ligand-receptor-G-protein ternary complex as a GTP-synthase. steady-state proton pumping and dose-response relationships for beta -adrenoceptors.
    Broadley KJ; Nederkoorn PH; Timmerman H; Timms D; Davies RH
    J Theor Biol; 2000 Jul; 205(2):297-320. PubMed ID: 10873440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations.
    Seifert R; Wenzel-Seifert K; Gether U; Kobilka BK
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1218-26. PubMed ID: 11356949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonism and inverse agonism at dopamine D2-like receptors.
    Strange PG
    Clin Exp Pharmacol Physiol Suppl; 1999 Apr; 26():S3-9. PubMed ID: 10386247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulus amplification, efficacy, and the operational model. Part I--binary complex occupancy mechanisms.
    Trzeciakowski JP
    J Theor Biol; 1999 Jun; 198(3):329-46. PubMed ID: 10366490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the nature of the multivalency effect: a thermodynamic model.
    Kitov PI; Bundle DR
    J Am Chem Soc; 2003 Dec; 125(52):16271-84. PubMed ID: 14692768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiotidine, a histamine H2 receptor inverse agonist that binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model.
    Monczor F; Fernandez N; Legnazzi BL; Riveiro ME; Baldi A; Shayo C; Davio C
    Mol Pharmacol; 2003 Aug; 64(2):512-20. PubMed ID: 12869657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells.
    Nonno R; Lucini V; Pannacci M; Mazzucchelli C; Angeloni D; Fraschini F; Stankov BM
    Br J Pharmacol; 1998 Jun; 124(3):485-92. PubMed ID: 9647472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor binding kinetics and cellular responses of six N-formyl peptide agonists in human neutrophils.
    Waller A; Sutton KL; Kinzer-Ursem TL; Absood A; Traynor JR; Linderman JJ; Omann GM
    Biochemistry; 2004 Jun; 43(25):8204-16. PubMed ID: 15209517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evasive nature of drug efficacy: implications for drug discovery.
    Galandrin S; Oligny-Longpré G; Bouvier M
    Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
    Kenakin T
    Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug efficacy at G protein-coupled receptors.
    Kenakin T
    Annu Rev Pharmacol Toxicol; 2002; 42():349-79. PubMed ID: 11807176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the ligand-receptor-G protein ternary complex for GPCR drug discovery.
    Ratnala VR; Kobilka B
    Methods Mol Biol; 2009; 552():67-77. PubMed ID: 19513642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model.
    Roth BL; Choudhary MS; Khan N; Uluer AZ
    J Pharmacol Exp Ther; 1997 Feb; 280(2):576-83. PubMed ID: 9023266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
    Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rough set-based proteochemometrics modeling of G-protein-coupled receptor-ligand interactions.
    Strömbergsson H; Prusis P; Midelfart H; Lapinsh M; Wikberg JE; Komorowski J
    Proteins; 2006 Apr; 63(1):24-34. PubMed ID: 16435365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.